Iterum Therapeutics Plc (ITRMF) Stock Price & Analysis
Iterum Therapeutics Plc (ITRMF) rose 0.00% to USD 0.05 as of June 10, 2026 at 03:12 UTC, according to Nexqual real-time market data.
ITRMF last closed at USD 0.05; the session ranged USD 0.05–0.05 on volume of 10,000 shares. Market capitalization is $2.66M, with a 52-week range of USD 0.01–1.28 (PNK). Source: Nexqual, June 10, 2026 at 03:12 UTC.
Key Statistics (as of June 10, 2026 at 03:12 UTC)
| Price | USD 0.05 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0.05 |
| Open | USD 0.05 |
| Day Range | USD 0.05 – 0.05 |
| 52-Week Range | USD 0.01 – 1.28 |
| Volume | 10,000 shares |
| Market Cap | $2.66M |
| Exchange | PNK |
Technical Analysis (ITRMF)
Nexqual's technical model rates ITRMF "NEUTRAL" based on 2 bullish and 3 bearish signals across 124 daily candles, as of June 10, 2026 at 03:12 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 51.21 (neutral) |
| vs SMA50 | Above (USD 0.04) |
| MACD | 0 (positive) |
Analyst Ratings (ITRMF)
Wall Street analysts rate ITRMF "None", per Nexqual as of June 10, 2026 at 03:12 UTC.
| Consensus Rating | None |
|---|---|
| Buy / Hold / Sell | 0 / 1 / 0 |
Earnings (ITRMF)
| Next Earnings Date | 2026-06-09 |
|---|---|
| Revenue Estimate | $410,000 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-09-30 | USD -0.2 vs est -0.09 ▼ miss |
| 2025-06-30 | USD -0.16 vs est -0.11 ▼ miss |
| 2025-03-31 | USD -0.14 vs est -0.14 ▲ beat |
| 2024-12-31 | USD -0.12 vs est -0.24 ▲ beat |
Source: Nexqual, June 10, 2026 at 03:12 UTC.
Financials & Fundamentals (ITRMF)
| Total Revenue | $390,000 |
|---|---|
| Gross Margin | +29.74% |
| Operating Margin | -1982.31% |
| Profit Margin | +0.00% |
| Current Ratio | 2.14 |
| Total Cash | $11.00M |
| Total Debt | $33.73M |
| Free Cash Flow | $-13.85M |
Source: Nexqual, June 10, 2026 at 03:12 UTC.
Financial Health Score (ITRMF)
Nexqual rates Iterum Therapeutics Plc's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 03:12 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $11M cash vs $34M debt |
| Cash Flow | Weak — Operating cash flow -$20M |
| Efficiency | Mixed — No data |
Ownership (ITRMF)
| Insider Ownership | +0.78% |
|---|---|
| Institutional Ownership | +5.86% |
| Shares Outstanding | 53.29M |
| Float | 52.37M |
| Short % of Float | +5.80% |
Source: Nexqual, June 10, 2026 at 03:12 UTC.
Leadership (ITRMF)
Iterum Therapeutics Plc is led by Michael W. Dunne (age 65), Strategic Advisor & Director, per Nexqual as of June 10, 2026 at 03:12 UTC.
| Strategic Advisor & Director | Michael W. Dunne (age 65) |
|---|---|
| Senior Vice President of Technical Operations | Tom Loughman |
| Senior Director of Legal Affairs & Company Secretary | Kevin Dalton |
Major Backers & Investors (ITRMF)
Notable institutional backers of Iterum Therapeutics Plc include HRT Financial LP, CAPTRUST Financial Advisors, Gen-wealth Partners Inc , according to Nexqual as of June 10, 2026 at 03:12 UTC.
Active Investors
| Investor | Stake |
|---|---|
| HRT Financial LP | 1.68% |
| CAPTRUST Financial Advisors | 0.26% |
| Gen-wealth Partners Inc | 0.16% |
| Jump Financial, LLC | 0.14% |
| Krilogy Financial, LLC | 0.13% |
Source: Nexqual, June 10, 2026 at 03:12 UTC.
From Iterum Therapeutics Plc's Latest SEC 10-K Filing (filed 2025-02-07)
Key Strengths & Strategy (as disclosed to the SEC)
- Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States.
- The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options.
- It is also developing sulopenem, a novel anti-infective compound with oral and intravenous formulations to treat uncomplicated urinatry tract infections, complicated urinary tract infections, and complicated intra-abdominal infections, as well as community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory diseases.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| VISL | Vislink Technologies, Inc. | USD 2.91 | ▲ 8.58% |
| CTRM | Castor Maritime Inc. | USD 2.18 | ▲ 2.35% |
| ARTL | Artelo Biosciences, Inc. | USD 1.33 | ▼ 3.62% |
| JAGX | Jaguar Health, Inc. | USD 2.82 | ▲ 0.71% |
| FAMI | Farmmi, Inc. Ordinary Shares | USD 1.12 | ▼ 1.75% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:12 UTC. This page is informational and not investment advice.